Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of navitoclax (ABT-263) monotherapy in platinum-resistant/refractory recurrent ovarian cancer
2015-000193-35Phase 2Completed
- Sponsor
- Centre François Baclesse
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of navitoclax in ovarian cancer, sponsored by Centre François Baclesse. Primary endpoint: Progression-free survival in overall cohort. Started Jul 2015; status: completed.
02
Drugs
navitoclax
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2015-000193-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000193-35.